ROME (ITALPRESS) – “The value of clinical trials” was held today, the webinar promoted by the High School of Economics and Management of Health Systems (ALTEMS) of the Catholic University to present the results of the work carried out under the responsibility scientific by Americo Cicchetti and the direction of Luca Angerame. The work was set up to measure the overall value contribution of clinical trials to the economic system in Italy, of which the first Report on the value of Clinical Trials 2020 provides a panoramic view. “It was a long and detailed work that represents an opportunity to provide elements in support of the institutions and industry to promote the competitiveness of the country. The economic value of research is made up of direct and indirect investments by both public and private, in addition to the generated induced, skilled employment and savings in the expenditure of the National Health Service “said Cicchetti. The Covid-19 pandemic has had among its effects that of bringing the clinical trials sector to the fore, mainly due to the large amount of studies that have been promoted in order to create effective vaccines and therapies. “From the pandemic we have learned that many studies are poorly done drugs and treatments, so it is important to invest in research. In one year Aifa has examined over 200 studies and approved 75, a great result, both for profit and non-profit. The role of research is fundamental to save life and guarantee high standards of care “says Nicola Magrini, Director of Aifa. The research has developed on three main directives: the qualitative description of the value of clinical research for the socio-economic system; the estimate of the economic value of the research, with a focus on the costs avoided by the National Health System thanks to the drugs provided free of charge by the companies promoting clinical trials (so-called “Averted Costs”); the photograph of the sector in the perception of the main production players, represented by a pool of 12 of the main pharmaceutical companies operating in Italy, and 12 companies affiliated to the Italian CRO Association (AICRO), as well as Farmindustria. In Italy, 672 new trials were approved in 2019, 23% of those approved by the EU. “The pharmaceutical industry – said Massimo Scaccabarozzi, president of Farmindustria – focuses heavily on research and development, in innovation. Every year 700 million are invested in clinical studies, 22% of the market share in Europe, 42% of which are on biotechnological drugs and 32% on rare diseases. This allows the patient not only to get to therapy earlier but to improve its effectiveness by ensuring resources for the national health system. For some time we have been asking for more simplifications, from time to cost and that implementing decrees are brought forward. Italy can play a leading role and Recovery will be important to strengthen our competitiveness “. For the deputy Beatrice Lorenzin “Approving the rules means helping the entire clinical trial sector and contributing to the development of research to provide patients with therapies that make the difference between life and death and that have an important impact on the country. “. The report underlined the importance of regulatory changes with the introduction of the European Regulation 536/14 which aims to reverse the trend towards the loss of global competitiveness of the EU in the sector. The strong demand for the efficiency of clinical research in our country determines the urgency of creating a strong alliance between politics, institutions and operators in the pharmaceutical industry to make clinical research in Italy a competitive and avant-garde development laboratory. (ITALPRESS). cga / pc / red 25-May-21 19:14
COPYRIGHT today © breaking latest news